Evidence map›Paper›PMID 26877848›Full record

ArticleIranian journal of basic medical sciences2015

Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: influences of the tumor stages and cytokine gene polymorphisms.

Abdollah Jafarzadeh, Kayhan Minaee, Ali-Reza Farsinejad, Maryam Nemati, Arezu Khosravimashizi, Hamid Daneshvar, Mohammad Mehdi Mohammadi, Abdolkarim Sheikhi, Abbas Ghaderi

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of basic medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Cimetidine and Ibuprofen Modulate T Cell Responses in a Mouse Model of Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  8. Article
  9. SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.International journal of hematology-oncology and stem cell research · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. BioMed research international · 2020
    Article
  17. The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox.International journal of molecular sciences · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Abdollah JafarzadehDepartment of Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
Kayhan MinaeeDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran; Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Ali-Reza FarsinejadDepartment of Laboratory Sciences, Paramedical School, Kerman University of Medical Sciences, Kerman, Iran.
Maryam NematiDepartment of Laboratory Sciences, Paramedical School, Kerman University of Medical Sciences, Kerman, Iran.
Arezu KhosravimashiziDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
Hamid DaneshvarDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
Mohammad Mehdi MohammadiDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
Abdolkarim SheikhiDepartment of Immunology, Medical School, Dezful University of Medical Sciences, Dezful, Iran.
Abbas GhaderiShiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Kerman University of Medical Sciences · IRDezful University of Medical Sciences · IRRafsanjan University of Medical Sciences · IRShiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIL-12 as an anti-tumor cytokine and IL-33 a novel identified cytokine with both pro- or anti-tumor activities, play important roles in response against tumor cells. Our aim was to evaluate the IL-12 and IL-33 levels and single nucleotide polymorphisms (SNP) in their genes in patients with breast cancer. MATERIALS AND

methodsBlood samples were collected from 100 patients with breast cancer, and 100 healthy women were controls. The serum IL-12 and IL-33 levels were measured by ELISA. The SNP rs3212227 (in IL-12 gene) and rs1929992 (in IL-33 gene) were determined using PCR-RFLP.

resultsThe IL-12 levels similarly expressed in patients and controls. IL-12 levels in patients at stage I were significantly lower than in the healthy group (P<0.05). IL-33 levels and the IL-33/IL-12 ratio were significantly higher in patients than the control group (P<0.001). The IL-33 levels and IL-33/IL-12 ratio in stage IV patients were significantly higher than other stages and controls (P<0.0001 and P<0.001, respectively). There were no significant differences in the frequencies of genotypes in rs3212227 and rs1929992 between patients and the control group. No significant differences were observed between subjects with various genotypes at rs3212227 and rs1929992 with respect to related cytokine levels.

conclusionThese results indicate that the diminished IL-12 production may contribute to the tumor establishment. The higher IL-33 levels and IL-33/IL-12 ratio in patients also indicate an imbalance in Th1/Th2 responses that may contribute to tumor development. Thus, correcting the imbalance of Th1/Th2 could be an important strategy for cancer immunotherapy.

Indexed as

Breast cancerInterleukin-12Interleukin-33Single nucleotide -polymorphismTumor stages

Identifiers

PMID26877848
PMCPMC4744358
OpenAlexW2223422862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.